ASCENTAGE PHARMA GROUP INTERNATIONAL
AAPGUnited States
4 filed reports · 347 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
4 reports · Dec 2024 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Annual · 20-FSEC EDGAR | 2 | 2,036 | Dec 2024 to Dec 2025 |
| Interim · 6-KSEC EDGAR | 2 | 44 | Jun 2025 to Jun 2026 |
Financial data
347 concepts · 2,080 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial339 concepts · 2,011 facts · Dec 2021 to Jun 2026
- Interest-bearing bank and other borrowings20 · Dec 2023 to Dec 2025
- Cash and cash equivalents16 · Dec 2021 to Dec 2025
- Rightofuse assets16 · Dec 2022 to Dec 2025
- Equity14 · Dec 2021 to Dec 2025
- Government grants14 · Dec 2022 to Dec 2025
- Lease liabilities14 · Dec 2022 to Dec 2025
- Share capital14 · Dec 2021 to Dec 2025
- Carrying Amounts [member]12 · Dec 2023 to Dec 2025
- Cash and bank balances at central banks12 · Dec 2022 to Dec 2025
- Net deferred tax liabilities12 · Dec 2022 to Dec 2025
- Non cash addition for right of use assets and lease liabilities12 · Dec 2022 to Dec 2025
- Noncurrent financial assets (IFRS)12 · Dec 2022 to Dec 2025
- Restricted cash and cash equivalents (IFRS)12 · Dec 2022 to Dec 2025
- Time deposits with original maturity of more than three months12 · Dec 2022 to Dec 2025
- Accruals classified as current10 · Dec 2023 to Dec 2025
- Accumulated other comprehensive income10 · Dec 2023 to Dec 2025
- Assets less current liabilities10 · Dec 2023 to Dec 2025
- Balances with banks10 · Dec 2023 to Dec 2025
- Borrowings10 · Dec 2023 to Dec 2025
- Capital and reserves10 · Dec 2023 to Dec 2025
- Contract liabilities10 · Dec 2023 to Dec 2025
- Cost10 · Dec 2023 to Dec 2025
- Current accrued expenses and other current liabilities10 · Dec 2023 to Dec 2025
- Current assets10 · Dec 2023 to Dec 2025
Product3 concepts · 38 facts · Dec 2022 to Dec 2025
- Revenue21 · Dec 2022 to Dec 2025
- Cost of sales12 · Dec 2022 to Dec 2025
- Revenue that was included in contract liability balance at beginning of period5 · Dec 2022 to Dec 2024
Geography5 concepts · 31 facts · Dec 2022 to Dec 2025
- Tax effect of tax losses10 · Dec 2023 to Dec 2025
- Applicable tax rate9 · Dec 2022 to Dec 2025
- Revenue9 · Dec 2022 to Dec 2025
- High and New Technology Enterprise2 · Dec 2024 to Dec 2025
- Withholding tax1 · Dec 2024
Segments
69 factsFigures broken down by business line, region, product or another axis the company reports on.
Products and services5 members · 36 facts
- Others13 · Dec 2022 to Dec 2025
- Products12 · Dec 2022 to Dec 2025
- Types Of Goods Or Services6 · Dec 2022 to Dec 2025
- Commercialization Rights Income4 · Dec 2022 to Dec 2024
- Intellectuall Property1 · Dec 2024
Statement geographical5 members · 21 facts
- Chinese Mainland9 · Dec 2022 to Dec 2025
- US5 · Dec 2022 to Dec 2025
- HK3 · Dec 2022 to Dec 2024
- CH2 · Dec 2024
- Suzhou Yasheng2 · Dec 2024 to Dec 2025
Geographical areas2 members · 10 facts
- Chinese Mainland5 · Dec 2023 to Dec 2025
- US5 · Dec 2023 to Dec 2025
Product or service1 member · 2 facts
- Intellectuall Property2 · Dec 2024
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.